HS-276

HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research[1].

Product Specifications

CAS Number

[2767422-72-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Casein Kinase; IRAK; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/hs-276.html

Purity

98.93

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; adjust pH to 2 with 1M HCl; heat to 60°C)

Smiles

O=C(C1=CC=CC(C(NC2=NC3=C(N2CCC)C=C(CN4CCCCC4)C=C3)=O)=C1)N

Molecular Formula

C24H29N5O2

Molecular Weight

419.52

Precautions

H302, H315, H319

References & Citations

[1]Scarneo S, et al. Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis. ACS Chem Biol. 2022 Mar 18;17 (3) :536-544.